Cartesian Therapeutics

196 articles about Cartesian Therapeutics

• Selecta Announces Second Quarter 2016 Financial Results And Provides Corporate Update

  8/9/2016

• Selecta Announces Gene Therapy Programs For Two Rare Genetic Metabolic Disorders

  7/19/2016

• With Selecta's $70 Million IPO, Mass Biotechs Raised a Total of $376 Million This Year

  6/24/2016

• Selecta's IPO Expected Next Week; Sixth Biotech in Massachusetts to Go Public This Year

  6/20/2016

• Selecta Obtains Exclusive License To Proprietary Gene Therapy Vector From Massachusetts Eye And Ear

  5/19/2016

• Selecta Continues To Successfully Advance Pipeline Of Novel Immunotherapeutic Candidates

  10/16/2015

• Selecta Appoints Earl E. Sands, MD, As Chief Medical Officer

  9/8/2015

• Massachusetts' Selecta Banks Another $38 Million

  9/8/2015

• Selecta’ Synthetic Vaccine Particles Instrumental In Breakthrough Research On Mucosal Vaccines

  6/19/2015

• Selecta Initiates Phase 1 Clinical Program Of SEL-212, Designed As The First Non-Immunogenic Biologic Treatment For Gout

  6/10/2015

• Selecta And Genethon Collaborate To Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform

  5/13/2015

• Sanofi Adds Celiac Disease to the Menu With $300 Million Selecta Bet

  5/13/2015

• Selecta Biosciences, Inc. To Webcast Presentation At Needham & Company’s 14th Annual Healthcare Conference

  4/6/2015

• Selecta Biosciences, Inc. And Skolkovo Foundation Collaboration To Develop A Synthetic Vaccine Particle In The Field Of Immuno-Oncology

  12/23/2014

• Selecta Biosciences, Inc., Juvenile Diabetes Research Foundation And Sanofi Extend Collaboration To Develop A Synthetic Vaccine Particle Immunotherapy For Type 1 Diabetes

  10/15/2014

• Selecta Biosciences, Inc. Announces More Than $20 Million In Equity Funding

  10/15/2014

• 3SBio Inc. Exclusively Licenses Pegsiticase (Uricase PEG-20) To Selecta Biosciences, Inc. To Develop Drug Candidate To Treat Gout

  6/18/2014

• Selecta Biosciences, Inc. To Accelerate Program For Novel Dual Action Vaccine For Malaria

  6/17/2014

• Selecta Biosciences, Inc. Enters Into Exclusive License Agreement With 3SBio Inc. To Develop Drug Candidate To Treat Gout

  6/17/2014

• Selecta Biosciences, Inc. Accelerates Immune Tolerance Therapeutics And Announces New Product Candidate, SEL-212, For Refractory And Tophaceous Gout

  6/17/2014